Nanobac Pharmaceuticals, Inc. Launches Landmark Study To Explore Heart Disease Properties Of Calcifying Nanoparticles

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; “Nanobac” or “the Company”) and Mayo Clinic have reached an agreement to study whether calcifying nanoparticles, already found in atherosclerotic plaque, are infectious and contribute to the onset of heart disease.